clinical trial · NCT05562830
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Merck Sharp & Dohme LLC·phase2·active not recruiting·n = 48
Urothelial CarcinomaZilovertamab vedotinPembrolizumabMK-3120
brief summary
This substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1/ligand 1 (PD-1/L1) inhibitors. The protocol infrastructure will enable the rolling assignment of investigational treatments.
started
Nov 16, 2022
primary completion
Jun 20, 2028
completion
Jun 20, 2028
last updated
Apr 2, 2026
official title
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol